<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2006-07-19">19 July 2006</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>DSc</roleName><forename type="first">Hannu</forename><surname>Koistinen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Neurodegeneration Research Department</orgName>
								<orgName type="institution">GlaxoSmithKline Research &amp; Development Ltd</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">New Frontiers Science Park</orgName>
								<address>
									<addrLine>Third Avenue</addrLine>
									<settlement>Harlow, Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Rab</forename><surname>Prinjha</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Neurodegeneration Research Department</orgName>
								<orgName type="institution">GlaxoSmithKline Research &amp; Development Ltd</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">New Frontiers Science Park</orgName>
								<address>
									<addrLine>Third Avenue</addrLine>
									<settlement>Harlow, Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BSc</roleName><forename type="first">Peter</forename><surname>Soden</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Neurodegeneration Research Department</orgName>
								<orgName type="institution">GlaxoSmithKline Research &amp; Development Ltd</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">New Frontiers Science Park</orgName>
								<address>
									<addrLine>Third Avenue</addrLine>
									<settlement>Harlow, Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BSc</roleName><forename type="first">Alex</forename><surname>Harper</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Neurodegeneration Research Department</orgName>
								<orgName type="institution">GlaxoSmithKline Research &amp; Development Ltd</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">New Frontiers Science Park</orgName>
								<address>
									<addrLine>Third Avenue</addrLine>
									<settlement>Harlow, Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Steven</forename><forename type="middle">J</forename><surname>Banner</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Institute of Psychiatry</orgName>
								<orgName type="institution" key="instit2">King&apos;s College London</orgName>
								<address>
									<addrLine>Denmark Hill</addrLine>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pierre-François</forename><surname>Pradat</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jean-Philippe</forename><surname>Loeffler</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Faculte ´de Me ´decine</orgName>
								<orgName type="laboratory">Laboratoire de Signalisations Mole ´culaires et Neurode ´gene ´rescence</orgName>
								<orgName type="institution">Universite ´Louis Pasteur</orgName>
								<address>
									<postCode>3433</postCode>
									<settlement>Strasbourg</settlement>
									<region>EA</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Colin</forename><surname>Dingwall</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Neurodegeneration Research Department</orgName>
								<orgName type="institution">GlaxoSmithKline Research &amp; Development Ltd</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">New Frontiers Science Park</orgName>
								<address>
									<addrLine>Third Avenue</addrLine>
									<settlement>Harlow, Essex</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution" key="instit1">Pharmaceutical Science Research Divi-sion, King&apos;s College London</orgName>
								<orgName type="institution" key="instit2">Franklin Wilkins Bldg</orgName>
								<address>
									<addrLine>150 Stamford St</addrLine>
									<postCode>SE1 9NH</postCode>
									<settlement>Lon-don</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Muscle &amp; Nerve</title>
						<title level="j" type="abbrev">Muscle Nerve</title>
						<idno type="ISSN">0148-639X</idno>
						<idno type="eISSN">1097-4598</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">34</biblScope>
							<biblScope unit="issue">4</biblScope>
							<biblScope unit="page" from="444" to="450"/>
							<date type="published" when="2006-07-19">19 July 2006</date>
						</imprint>
					</monogr>
					<idno type="MD5">D48D58E470702191C435E6CFA5A6007D</idno>
					<idno type="DOI">10.1002/mus.20612</idno>
					<note type="submission">Accepted 15 May 2006</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2" ident="GROBID" when="2023-03-30T18:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>A␤, ␤-amyloid peptide</term>
					<term>ALS, amyotrophic lateral sclerosis</term>
					<term>APP, amyloid precursor protein</term>
					<term>PS1, presenilin 1</term>
					<term>RT-PCR, reverse transcription-polymerase chain reaction</term>
					<term>SDS, sodium dodecylsulfate</term>
					<term>SDS-PAGE, SDS-polyacrylamide gel electrophoresis</term>
					<term>SOD1, Cu/Zn-dependent superoxide dismutase</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease defined by motor neuron loss. Transgenic mouse models show features that closely mimic those seen in the clinical situation, reflected in the molecular changes observed in mouse models and in tissues from patients. We report a dramatic increase in the expression of amyloid precursor protein (APP) in the hindlimb muscles, but not the spinal cord of the G93A transgenic mouse model, significantly before the appearance of clinical abnormalities. APP levels were unchanged in nontransgenic mice and in mice overexpressing human wild-type Cu/Zn-dependent superoxide dismutase 1 (SOD1). Preliminary results indicate a similar change in APP expression in human deltoid muscle samples from ALS patients compared with age-matched controls. The inhibitory role of APP in innervation at the neuromuscular junction and increased expression in inclusion-body myositis suggest that presymptomatic upregulation of APP may be consistent with a potential role for APP in ALS pathology.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>by degeneration of upper and lower motor neurons, and muscle atrophy leading to muscle weakness. Failure of pulmonary function and death usually ensue within 5 years of the first appearance of symptoms. <ref type="bibr" target="#b5">6</ref> Approximately 10% of ALS cases are familial, and mutations in the cytoplasmic Cu/Zn superoxide dismutase 1 (SOD1) gene account for approximately 20% of these. <ref type="bibr" target="#b5">6</ref> To date, more than 100 different SOD1 mutations are known. Much of ALS research has involved transgenic animal models expressing human SOD1 carrying disease-linked mutations. <ref type="bibr" target="#b34">35</ref> Despite the fact that mutations in SOD1 have been found in a small percentage of all ALS cases, a key advantage of these models is that they offer the opportunity to study cellular, neurological, and biochemical changes in the presymptomatic stages of the disease, making it possible to delineate the disease-initiating processes. <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b34">35</ref> The majority of the disease-linked mutations in SOD1 do not affect enzyme activity as compared with wild-type SOD1, suggesting that the pathology is not induced by a failure to clear reactive oxygen species. <ref type="bibr" target="#b23">24</ref> Furthermore, studies in mice that overexpress wild-type SOD1 have shown variable effects ranging from a complete absence of motor neuron disease to a modest impairment in motor performance at advanced age, <ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b30">31</ref> whereas targeted deletion of SOD1 has no deleterious effect. <ref type="bibr" target="#b24">25</ref> These observations have led to general agreement that mutations in SOD1 induce ALS pathology due to a gain of toxic function. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b14">15</ref> However, the precise mechanism by which mutant SOD1 induces ALS pathology in ALS or induces ALS-like symptoms in transgenic mouse models is unknown. <ref type="bibr" target="#b5">6</ref> Most transgenic mouse models express the mutant human SOD1 in the same tissues as SOD1 is expressed in humans. The ubiquitous tissue expression means that it is unclear whether any particular cell type is more important than others in the neurodegenerative process. Surprisingly, studies have shown that specific neuronal or astrocytic expression of mutant SOD1 in transgenic animals does not result in motor neuron degeneration, apparently eliminating them as the sole mediators of pathology. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b18">19</ref> Structural changes in muscle and loss of neuromuscular junctions are common in both ALS mice and patients, <ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b35">36</ref> raising the possibility that changes in muscle rather than neurons or astrocytes are key early events in the pathogenesis of ALS.</p><p>Research on amyloid precursor protein (APP) has largely focused on its role in Alzheimer's disease, because mutations in APP are associated with familial forms of the disease. <ref type="bibr" target="#b27">28</ref> There also appears to be a general involvement of the APP-processing pathway in neurodegeneration. <ref type="bibr" target="#b9">10</ref> In skeletal muscle, APP has been localized to the base of the postsynaptic folds of the neuromuscular junction, but its function is unclear. <ref type="bibr" target="#b3">4</ref> Increased levels of APP have been detected in the muscles of patients with inclusion-body myositis, where it seems to play a pathogenic role. <ref type="bibr" target="#b2">3</ref> Overexpression of APP in transgenic mice using a musclespecific promoter induces a phenotype resembling inclusion-body myositis, <ref type="bibr" target="#b28">29</ref> and overexpression in cells, using a viral delivery system, inhibits innervation in vitro. <ref type="bibr" target="#b20">21</ref> These findings have led to the suggestion that APP has a central role in the pathology of inclusion-body myositis. <ref type="bibr" target="#b2">3</ref> In addition, BACE1, a key protease in the generation of ␤-amyloid peptide (A␤) from APP, is also overexpressed in the muscles of patients with inclusion-body myositis. <ref type="bibr" target="#b31">32</ref> Given a clear pathogenic role for A␤ in Alzheimer's disease and a potential pathogenic role for APP and A␤ in inclusion-body myositis, we examined the expression of APP and APP-processing enzymes, BACE1 and presenilin 1 (PS1), in the muscles of ALS patients and a mouse model of ALS.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Human Muscle Samples.</head><p>Human deltoid muscle biopsies were obtained by standard surgical procedure from six patients attending the ALS Center of the Pitie ´-Salpe ˆtrie `re Hospital (Paris, France). The patients (four men and two women) had probable or definite sporadic ALS in accordance with the World Federation of Neurology criteria. <ref type="bibr" target="#b4">5</ref> One had bulbaronset and five had limb-onset disease. Their mean age was 60.7 years (range, 35-79 years). Mean duration of the disease was 32.3 months (range, 6.7-58.6 months). The control group included four men and two women without any significant neurological history (mean age, 64 years; range, 39 -82 years), whose deltoid muscle specimens were taken during orthopedic surgery. Samples were immediately frozen in liquid nitrogen and stored at Ϫ80°C until analyzed. The study was approved by the local ethics committee, and patients signed an informed consent document consistent with institutional guidelines.</p><p>Mouse Tissues. G1H mice [B6SJL-TgN(SOD1-G93A)1Gur] carrying approximately 25 copies of the G93A mutant allele of human SOD1 (referred hereafter as ALS mice) were obtained from Jackson Laboratories (Bar Harbor, Maine). <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b14">15</ref> Nontransgenic littermates served as wild-type controls, and B6SJL-TgN(SOD1)2Gur mice (Jackson Laboratories) served as controls overexpressing wild-type human SOD1. Brain, spinal cord, and lower forelimb arm and hindlimb (gastrocnemius) muscle tissues were dissected from 34 -132-day-old mice, briefly rinsed in phosphate-buffered saline (PBS), and frozen in liquid nitrogen prior to biochemical analyses. For immunohistochemical studies, samples were fixed for 2 days in 3% paraformaldehyde in 0.1 M sodium phosphate buffer, pH 7.4. All experiments complied with the UK Animals (Scientific Procedures) Act of 1986 and strictly conformed to GlaxoSmithKline ethical standards.</p><p>Immunoblotting. Human tissues were homogenized in PBS containing 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate (SDS), 0.5% aprotinin, 5 mM dithiothreitol, and 1 mM phenylmethylsulfonylfluoride. Homogenates were boiled for 5 min and sonicated for 30 seconds. Mouse tissues were mechanically homogenized in lysis buffer [50 mM Tris, pH 7.5, containing 150 mM NaCl, 0.1% SDS, 1% Triton X-100, and protease inhibitors (Complete Mini; Roche, Lewes, UK)]. Cellular debris was removed by centrifugation and protein concentration was determined using a bicinchoninic acid assay or the DC Protein Assay (Bio-Rad, Hercules, California). Tissue lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with specific antibodies as follows: anti-actin (C4; ICN Biomedicals, Aurora, OH), 1:1000; anti-APP (CT695; Zymed, San Francisco, California), 1 g/ml for mouse APP immunoblotting; chicken anti-APP against peptide fragment APP66-81, <ref type="bibr" target="#b19">20</ref> 1:500 for human APP immunoblotting; anti-BACE1 monoclonal 9B21, 16 1 g/ml; and anti-SOD1 PC077 (The Binding Site, Birmingham, UK), 1 g/ml. Bound antibodies were detected using horseradish peroxidasecoupled secondary antibodies (Dako, Glostrup, Denmark) and enhanced chemiluminescence. Equal loading of mouse samples was confirmed by Ponceau S staining and immunoblotting for actin. Equal loading of human samples was confirmed by Ponceau S staining. The relative optical density of immunoreactive bands was quantified using Multi-Analyst and Molecular Analyst software (both from Bio-Rad).</p><p>Amyloid Immunoassay. Levels of rodent ␤-amyloid peptides (A␤ 40 and A␤ 42) in hindlimb muscle lysates of 34 -110-day-old wild-type and ALS mice were measured using a sensitive sandwich-type immunoassay. Muscle tissues were lysed using lysis buffer or 5 M guanidine hydrochloride in PBS, containing protease inhibitors (Complete Mini, Roche). After tenfold dilution in assay buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.05% Tween-20, 1% bovine serum albumin), samples contained 2.2 Ϯ 1.3 mg protein/ml (lysis buffer lysates) or 2.3 Ϯ 1.0 mg protein/ml (guanidine buffer lysates). The levels of A␤ 40 and A␤ 42 were measured in these extracts using a sensitive immunoassay (BioVeris, Gaithersburg, MD) employing A␤ C-terminal specific antibodies. Briefly, A␤ peptides were captured using biotinylated G49 (Signet Laboratories, Dedham, Massachusetts). BioVeris-tagged 5G5 and G210 (The Genetics Co., Schlieren, Switzerland) antibodies were used to detect the specific A␤ species. Antibody-A␤ complexes were captured with streptavidincoated Dynabeads (BioVeris) and assayed in an M8 analyzer. Standard curves were constructed using rodent A␤ 40 and A␤ 42 peptides in assay buffer containing 0.5 M guanidine hydrochloride. Data was analyzed using Prism software (GraphPad Software, San Diego, California).</p><p>Immunohistochemical Staining. Phosphate-buffered, paraformaldehyde-fixed, paraffin-embedded tissues were stained using 5 g/ml anti-APP antibody (CT695, Zymed) and the Envisionϩ System (Dako). Briefly, 5-m sections were dewaxed and dehydrated, followed by 5-min proteinase K treatment to retrieve antigen. Sections were treated for 5 min with peroxidase block (Dako) and incubated for 10 -20 min with serum-free protein block (Dako). Primary antibody was incubated for 1 h at room temperature or overnight at 4°C, followed by 30 -40-min incubation with anti-rabbit antibodies conjugated with horseradish peroxidase-labeled polymer, and DABϩ substrate-chromogen (all by the Dako Envisionϩ System). SOD1 Activity Assay. SOD1 activity was measured in tissue lysates (1 g protein/ml lysis buffer), which were diluted 1:20 in 2.1% SDS to inhibit Mn-SOD activity. <ref type="bibr" target="#b12">13</ref> After 30-min incubation at 37°C, SOD1 activity was measured using the WST SOD Assay Kit (Dojindo Molecular Technologies, Tokyo, Japan). Pure SOD1 enzyme from Sigma (St. Louis, Missouri) was used as a standard.</p><p>Quantitative RT-PCR. Messenger RNA was quantitated by TaqMan RT-PCR as described previously. <ref type="bibr" target="#b21">22</ref> RNA was extracted from frozen tissues using Trizol (Invitrogen, Paisley, UK) and 1 g was transcribed using Superscript II reverse transcriptase (Invitrogen) and an oligo-dT primer. Each cDNA synthesis reaction was performed in triplicate and an additional negative control reaction was performed without reverse transcriptase. Primers and fluorogenic probes are shown in Table <ref type="table" target="#tab_0">1</ref>. ␤-actin, cyclophilin, and glyceraldehyde-3-phosphate dehydrogenase were used to normalize expression levels.</p><p>Identification of Splice Variants by RT-PCR. For detection of APP and BACE1 splice variants, primers flanking specific intron-exon junctions were de- Rat ␤-actin, cyclophilin, and GAPDH primers and probes are described elsewhere. <ref type="bibr" target="#b21">22</ref> signed: APP: 5Ј AGT GAA GAC AAA GTA GTA GAA GT 3Ј (sense primer) and 5Ј GCC TCT CTT TGG CTT TCT GG 3Ј (antisense primer); BACE1: 5Ј AGG CAG CTG TCC AGC ACA TA 3Ј (sense) and 5Ј TCA TAA TAC CAC TCC CGC CG 3Ј (antisense). RT-PCR was performed using cDNA prepared as for quantitative RT-PCR. Reactions were carried out using a PCR reaction mix (REDTaq ReadyMix; Sigma).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>We examined the muscle and spinal cord of the [B6SJL-TgN(SOD1-G93A)1Gur] mice, the mouse model of ALS, and found significant, 3.4 -4-fold increases in the levels of APP in the hindlimb (gastrocnemius) muscle at 70 days of age (Fig. <ref type="figure" target="#fig_0">1A</ref>), which is approximately 3 weeks before the first appearance of clinical signs. This elevation was not detectable in animals aged 45 days (Fig. <ref type="figure" target="#fig_0">1A</ref>), but became detectable at day 60 and was pronounced by day 70 (Fig. <ref type="figure" target="#fig_0">1A</ref>, G93A, and data not shown). Increased APP levels were confirmed with additional antibodies that recognize the amyloid domain (1E8), <ref type="bibr" target="#b1">2</ref> an N-terminal epitope (22C11 that also recognizes the APP homolog APLP2), <ref type="bibr" target="#b33">34</ref> and a C-terminal epitope of APP (Ab54). <ref type="bibr" target="#b17">18</ref> By contrast, in nontransgenic wild-type mice (Fig. <ref type="figure" target="#fig_0">1A</ref>, NT) or control mice overexpressing wild-type human SOD1, APP levels remained low, even in animals over 100 days of age (Fig. <ref type="figure" target="#fig_0">1B</ref>, wtSOD, and data not shown). In the spinal cord, although the overall levels of APP were consistently higher than in the muscle, no differences in protein level between ALS and wild-type control mice were detected (Fig. <ref type="figure" target="#fig_0">1A</ref>).</p><p>Immunohistochemical staining showed that APP was localized throughout the muscle fibers, the staining being more intense in atrophied muscle cells than in wild-type mouse muscles (Fig. <ref type="figure" target="#fig_0">1C</ref>). SOD1 protein levels and enzymatic activity in all transgenic tissues studied (brain, spinal cord, and lower forelimb arm and hindlimb gastrocnemius muscle) were constant with respect to age, being much higher in transgenic than in corresponding wild-type mouse tissues (Fig. <ref type="figure" target="#fig_0">1A</ref> and data not shown).</p><p>To confirm the identity of the APP isoform expressed in muscle, we carried out RT-PCR reactions and the results indicated that the primary APP transcript in muscle was the APP770 isoform; the shorter isoform (APP695) was expressed in spinal cord and brain (Fig. <ref type="figure" target="#fig_1">2A</ref>). To determine whether the higher APP protein level observed in ALS mouse muscle was due to an elevation of mRNA levels, we carried out quantitative PCR reactions. We used Nogo-A as a positive control as it is an example of an mRNA that is significantly upregulated in ALS. <ref type="bibr" target="#b8">9</ref> We found that APP mRNA levels in ALS mouse muscle were increased 1.7-fold, which, although significant, was less than the 8.4-fold upregulation of Nogo-A found here (Fig. <ref type="figure" target="#fig_1">2B</ref>). In contrast, messenger RNA levels of PS1 [mutant G93A wild-type SOD1 transgene and endogenous mouse SOD1 (mSOD1)] proteins in hindlimb muscle and spinal cord lysates of ALS mice (G93A) and mice expressing wild-type human SOD1. For A and B, 25 g or 10 g protein extracted from hindlimb muscles or spinal cords, respectively, were applied to each lane of SDS-PAGE gel, except for SOD1 immunoblotting 10 g protein/lane was used for all samples. (C) Immunohistochemical staining of APP in hindlimb muscle of ALS (G93A) and nontransgenic (NT) control mice. Inset in G93A panel represents a negative control in which preimmune rabbit immunoglobulin was used instead of APP antibody. All samples are from 104day-old mice. Scale bar ϭ 50 m. and BACE1 did not differ significantly between wildtype and ALS mice (Fig. <ref type="figure" target="#fig_1">2B</ref>) and, although expressed, no changes in BACE1 protein levels could be detected. BACE1 expressed in the muscles is likely to represent the active form of the enzyme as RT-PCR showed that the majority of BACE1 transcripts corresponded to mRNA encoding the full length-that is, the proteolytically active, BACE1 isoform (Fig. <ref type="figure" target="#fig_1">2A</ref>)-rather than the alternatively spliced enzymatically inactive isoforms. <ref type="bibr" target="#b29">30</ref> Despite the increase in APP levels and the presence of mature BACE1, we detected very low levels of A␤ in muscle tissue using a sensitive immunoassay. As the pathology progressed in the ALS mouse tissue, these low levels of A␤ did not change compared to wild-type mouse tissue.</p><p>In order to determine whether similar changes in APP levels could be detected in the muscle of ALS patients, we obtained deltoid muscle biopsy material from six sporadic ALS patients and six controls, and analyzed the levels of APP in the tissue by immunoblotting. The results showed approximately fourfold higher APP levels in human ALS muscle than in age-matched controls (Fig. <ref type="figure" target="#fig_2">3</ref>), quantitatively similar to the increase we detected in ALS mice.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In this styudy we have reported an increase in APP level in the muscles of the G93A SOD1 mouse model of ALS. This increase preceded the onset of disease signs, such as altered gait and shaking or tremor in the hindlimbs, <ref type="bibr" target="#b6">7</ref> by at least 20 days. Similarly, markedly higher APP levels were observed in the deltoid muscles of patients with sporadic ALS, as compared with non-ALS individuals who had no significant neurological history.</p><p>Different isoforms of APP are expressed in a tissue-specific manner. Of the major isoforms, APP770 and APP751 are expressed in virtually all peripheral tissues and the adult brain, whereas APP695 is particularly enriched in the nervous system. <ref type="bibr" target="#b25">26</ref> Our results suggest the same isoform distribution in the ALS mouse model, indicating that there was no switch in the APP isoform associated with pathology.</p><p>Studies of the chronology of molecular and pathological changes in a number of ALS mouse models has provided a clear progression of events that precede the appearance of physical signs in the animals. <ref type="bibr" target="#b5">6,</ref><ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b34">35</ref> Such analyses have the potential to identify the earliest events in disease progression and hence potential therapeutic targets. The increases in APP and BACE1 transcripts were detected in ALS (G93A) and nontransgenic (NT) mouse hindlimb muscles by RT-PCR using primers flanking alternatively spliced exons. APP was also detected in mouse spinal cord and brain. (B) Messenger RNA levels in 85-90-day-old ALS mice (G93A) hindlimb muscles in relation to expression in NT control mice, as detected by quantitative RT-PCR. Levels are expressed as percentage of expression in nontransgenic mice. Bars represent mean ϩ SD. n ϭ 3 for transgenic and n ϭ 2 for nontransgenic mouse tissues. APP and Nogo-A expression are significantly higher in transgenic mouse muscle (P Ͻ 0.02 for both, t-test). APP levels that we observed occur very early in the disease process; the only earlier change in the muscle that has been documented in this model is the degeneration of neuromuscular junctions. <ref type="bibr" target="#b10">11</ref> The focus of pathological analysis has been the motor neuron and, consequently, the majority of documented presymptomatic changes have been reported for this tissue. These changes include vacuolation and mitochondrial swelling, fragmentation of the Golgi apparatus, and appearance of neurofilament-rich inclusions. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b22">23</ref> Therefore, it is generally thought that the pathology originates from the degeneration of these cells. However, some of these early changes in motor neurons have also been found in transgenic mice overexpressing wild-type SOD1. <ref type="bibr" target="#b7">8</ref> These mice do not develop ALS-like signs, suggesting that not all of these changes are relevant to the pathology. We have found that, even at an advanced age, mice overexpressing wild-type human SOD1 had similar APP levels to nontransgenic wild-type control mice or young ALS mice. This suggests that higher APP levels in the muscle are linked to the gain of toxic function caused by the mutation in SOD1, rather than the overexpression of SOD1 protein or increases in SOD1 activity. Our results, coupled with recent studies showing that motor neuron or astrocyte-restricted expression of mutant SOD1 is not sufficient to cause signs of ALS in mice, <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b18">19</ref> has led us to suggest that changes in muscles are important in the pathogenetic cascade leading to ALS. Clearly, the generation of a mouse model using a muscle-specific promoter to drive expression of mutant SOD1 would be particularly valuable.</p><p>Our results, and the observations that APP mRNA and protein levels are increased in the developing neuromuscular junction and in regenerating muscles in a variety of neuromuscular and muscle diseases, <ref type="bibr" target="#b26">27</ref> raise the question of the significance of the elevated levels of APP in muscle. A clue may be found in studies of inclusion-body myositis in which many pathological changes, including overexpression of APP and the presence of A␤ deposits and hyperphosphorylated tau in the form of paired helical filaments, have been reported in muscles, suggesting interesting parallels between Alzheimer's disease and inclusion-body myositis. <ref type="bibr" target="#b3">4</ref> It has been proposed that, in inclusion-body myositis, overexpression of APP occurring within the aging muscle fibers is an early upstream event that induces the subsequent pathological cascade. <ref type="bibr" target="#b3">4</ref> Muscle-specific overexpression of APP in transgenic mice using the muscle creatine kinase promoter induces a phenotype resembling inclusion-body myositis, although the levels of A␤ are very low. <ref type="bibr" target="#b28">29</ref> These results are consistent with our findings and suggest that elevation of APP levels in inclusion-body myositis and in ALS could have direct pathogenic effects, independent of the level of A␤. This is also consistent with in vitro data in cultured human muscle cells in which overexpression of APP using viral vectors prevented the formation of neuromuscular junctions by inhibiting their innervation. <ref type="bibr" target="#b20">21</ref> Therefore, the weight of this evidence is consistent with a pathogenic role for elevated levels of APP.</p><p>A complex pattern of denervation, reinnervation, and compensatory sprouting has been found to take place in skeletal muscles before detectable loss of motor neurons in the spinal cord. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b10">11,</ref><ref type="bibr" target="#b11">12</ref> It has also been shown that, after early loss of axons, there is an increase in axon number late in the pathology in the G93A model. <ref type="bibr" target="#b10">11</ref> Therefore, it is also possible that APP plays a positive role in the reinnervation and sprouting process, consistent with the demonstration of neurotrophic properties of the protein. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b32">33</ref> There is currently insufficient data to allow us to discriminate unambiguously between a positive, protective role for APP and a pathological role. However, experimental short-term denervation by axotomy induces a decline, rather than an elevation, in APP levels in intramuscular nerves and the neuromuscular junction, <ref type="bibr" target="#b0">1</ref> indicating that the elevated APP levels in the G93A mouse muscle represent a positively regulated, early response in pathogenesis.</p><p>As higher APP levels have also been reported in other muscle and neuromuscular diseases, APP might not represent an ALS-specific marker, <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b26">27</ref> but we suggest that APP might be useful as a presymptomatic diagnostic muscle biopsy marker in high-risk individuals, such as those having several family members with ALS.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIGURE 1 .</head><label>1</label><figDesc>FIGURE 1. (A)Immunoblots showing APP, actin (loading control), and SOD1 [mutant G93A SOD1 transgene and endogenous mouse SOD1 (mSOD1)] proteins in hindlimb muscle and spinal cord lysates of ALS mice (G93A) and wild-type nontransgenic mouse (NT) controls. SOD1 activity (U/ml) was measured by colorimetric assay. (B) Immunoblots showing APP and SOD1 [mutant G93A wild-type SOD1 transgene and endogenous mouse SOD1 (mSOD1)] proteins in hindlimb muscle and spinal cord lysates of ALS mice (G93A) and mice expressing wild-type human SOD1. For A and B, 25 g or 10 g protein extracted from hindlimb muscles or spinal cords, respectively, were applied to each lane of SDS-PAGE gel, except for SOD1 immunoblotting 10 g protein/lane was used for all samples. (C) Immunohistochemical staining of APP in hindlimb muscle of ALS (G93A) and nontransgenic (NT) control mice. Inset in G93A panel represents a negative control in which preimmune rabbit immunoglobulin was used instead of APP antibody. All samples are from 104day-old mice. Scale bar ϭ 50 m.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIGURE 2 .</head><label>2</label><figDesc>FIGURE 2. (A)Detection of APP and BACE1 splice variants. APP and BACE1 transcripts were detected in ALS (G93A) and nontransgenic (NT) mouse hindlimb muscles by RT-PCR using primers flanking alternatively spliced exons. APP was also detected in mouse spinal cord and brain. (B) Messenger RNA levels in 85-90-day-old ALS mice (G93A) hindlimb muscles in relation to expression in NT control mice, as detected by quantitative RT-PCR. Levels are expressed as percentage of expression in nontransgenic mice. Bars represent mean ϩ SD. n ϭ 3 for transgenic and n ϭ 2 for nontransgenic mouse tissues. APP and Nogo-A expression are significantly higher in transgenic mouse muscle (P Ͻ 0.02 for both, t-test).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 3 .</head><label>3</label><figDesc>FIGURE 3. APP immunoblot of deltoid muscle lysates of human ALS patients and controls, and respective quantitation of immunoreactive APP (*P Ͻ 0.05). Equal amounts of total protein were loaded on each lane.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Oligonucleotide primers and fluorogenic probes used in quantitative RT-PCR.</figDesc><table><row><cell>APP</cell><cell></cell></row><row><cell>Sense</cell><cell>5Ј AGC CCA GAA TCA GCT ACG GAA 3Ј</cell></row><row><cell>Antisense</cell><cell>5Ј GCT CCA CGG TGG TCT TGG TT 3Ј</cell></row><row><cell>Probe</cell><cell>5Ј ACG CTC TCA TGC CTT CGC TGA CG 3Ј</cell></row><row><cell>BACE1</cell><cell></cell></row><row><cell>Sense</cell><cell>5Ј CTT GCC ATG TGC ACG ATG AG 3Ј</cell></row><row><cell>Antisense</cell><cell>5Ј CAG TCT TCC ATG TCT GCC GTA AC 3Ј</cell></row><row><cell>Probe</cell><cell>5Ј CCT TCC ACT GCC GCC GTC CTG 3Ј</cell></row><row><cell>PS1</cell><cell></cell></row><row><cell>Sense</cell><cell>5Ј CAG TGG TTC TGG GAA CGA TGA 3Ј</cell></row><row><cell>Antisense</cell><cell>5Ј AGG CCC CAG GTG ACT GTC TC 3Ј</cell></row><row><cell>Probe</cell><cell>5Ј CCT CCC ACT CCT CAC TGA AGC CAC 3Ј</cell></row><row><cell>Nogo-A</cell><cell></cell></row><row><cell>Sense</cell><cell>5Ј TTG GTC CAA ACA TCA GAA GCT ATA</cell></row><row><cell></cell><cell>CA 3Ј</cell></row><row><cell>Antisense</cell><cell>5Ј GGA GTT GCT TCA GCT TCC TCA A 3Ј</cell></row><row><cell>Probe</cell><cell>5Ј CCA CAG CAC AGC TTT GCC CAT CA 3Ј</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="10974598" xml:id="foot_0">, 2006, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.20612 by University Of Illinois At Urbana Champaign, Wiley Online Library on [08/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1">MUSCLE &amp; NERVE October 2006 10974598, 2006, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/mus.20612 by University Of Illinois At Urbana Champaign, Wiley Online Library on [08/03/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The authors thank Dr. David Virley and Marion Perren for their assistance in mouse tissue collection, and GSK Laboratory Animal Sciences for animal husbandry, particularly Judith Latcham. H. Koistinen was supported by a Marie Curie Fellowship from the European Union, and S. J. Banner by the Motor Neurone Disease Association. J. P. Loeffler's laboratory is supported by the Association pour la Recherche sur la Scle ´rose Late ´rale Amyotrophique (ARS) and the Association pour la Recherche contre les Maladies Neurode ´ge ´ne ´ratives (AREMANE).</p></div>
			</div>

			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Neurotrophic regulation of mouse muscle ␤-amyloid protein precursor and ␣ 1 -antichymotrypsin as revealed by axotomy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Akaaboune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Festoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hantai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurobiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="503" to="514" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Studies on inhibition of ␤-amyloid formation in APP-751-transfected IMR-32 cells, and SPA4CT-transfected SHSY5Y cells</title>
		<author>
			<persName><forename type="first">D</forename><surname>Allsop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Christie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Markwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Owen</surname></persName>
		</author>
		<editor>Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM</editor>
		<imprint>
			<date type="published" when="1997">1997</date>
			<publisher>John Wiley &amp; Sons</publisher>
			<biblScope unit="page" from="717" to="727" />
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
	<note>Alzheimer&apos;s disease: biology, diagnosis and therapeutics</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-␤, cholesterol, relation to aging and to Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Rheumatol Rep</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="427" to="433" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Strong immunoreactivity of ␤-amyloid precursor protein, including the ␤-amyloid sequence, at human neuromuscular junctions</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="96" to="100" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Swash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Munsat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Amyotroph Lateral Scler Other Motor Neuron Disord</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="293" to="299" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Unraveling the mechanisms involved in motor neuron degeneration in ALS</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">I</forename><surname>Bruijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Cleveland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Neurosci</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="723" to="749" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Canto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Prattis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Neurosci</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="349" to="362" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS)</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dal Canto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gurney</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">676</biblScope>
			<biblScope unit="page" from="25" to="40" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dupuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gonzalez</forename><surname>De Aguilar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Di Scala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Rene</forename><forename type="middle">F</forename><surname>De Tapia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Dis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="358" to="365" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A portrait of Alzheimer secretases-new features and familiar faces</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">P</forename><surname>Esler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Wolfe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<biblScope unit="page" from="1449" to="1454" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Culver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tennant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castellano-Sanchez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="page" from="232" to="240" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases</title>
		<author>
			<persName><forename type="first">D</forename><surname>Frey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Borg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Spooren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Caroni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2534" to="2542" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A method for distinguishing Cu,Znand Mn-containing superoxide dismutases</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Geller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Winge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anal Biochem</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="86" to="92" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Parsadanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Andreeva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">D</forename><surname>Snider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Elliott</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="660" to="665" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Motor neuron degeneration in mice that express a human Cu</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gurney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Canto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Polchow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Alexander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Zn superoxide dismutase mutation. Science</title>
		<imprint>
			<biblScope unit="volume">264</biblScope>
			<biblScope unit="page" from="1772" to="1775" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Dingwall C. Characterization of the ectodomain shedding of the ␤-site amyloid precursor protein-cleaving enzyme 1 (BACE1)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Hussain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Shikotra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Riddell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Faller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="page" from="36264" to="36268" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Human Cu/Zn superoxide dismutase (SOD1) overexpression in mice causes mitochondrial vacuolization, axonal degeneration, and premature motoneuron death and accelerates motoneuron disease in mice expressing a familial amyotrophic lateral sclerosis mutant SOD1</title>
		<author>
			<persName><forename type="first">D</forename><surname>Jaarsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Haasdijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Grashorn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hawkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Van Duijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Verspaget</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="623" to="643" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Processing of the Alzheimer&apos;s disease amyloid precursor protein in Pichia pastoris: immunodetection of ␣-, ␤-, and ␥-secretase products</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Brocque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cappai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">X</forename><surname>Tanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Galatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochemistry</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="14958" to="14965" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Caroni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="4825" to="4832" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/ calmodulin protein kinase IV-dependent signaling pathway</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mbebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>See</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mercken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pradier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Loeffler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="20979" to="20990" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Impaired innervation of cultured human muscle overexpressing ␤APP experimentally and genetically: relevance to inclusion-body myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroreport</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3201" to="3205" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Medhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Read</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Robbins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Pangalos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci Methods</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="9" to="20" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Mourelatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K</forename><surname>Gonatas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gurney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dal</forename><surname>Canto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="5472" to="5477" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ratovitski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Corson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Strain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Cleveland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Culotta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="1451" to="1460" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Reaume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Elliott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Hoffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Kowall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ferrante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Siwek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="43" to="47" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">␤A4-amyloid protein precursor mRNA isoforms without exon 15 are ubiquitously expressed in rat tissues including brain, but not in neurons</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sandbrink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Masters</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beyreuther</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="1510" to="1517" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Expression of ␤-amyloid precursor protein gene is developmentally regulated in human muscle fibers in vivo and in vitro</title>
		<author>
			<persName><forename type="first">E</forename><surname>Sarkozi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="27" to="33" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Alzheimer&apos;s disease: genes, proteins, and therapy</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Selkoe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="page" from="741" to="766" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Inclusion body myositis-like phenotype induced by transgenic overexpression of ␤APP in skeletal muscle</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sugarman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Oddo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Echegoyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Golde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="6334" to="6339" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Three novel alternatively spliced isoforms of the human beta-site amyloid precursor protein cleaving enzyme (BACE) and their effect on amyloid beta-peptide production</title>
		<author>
			<persName><forename type="first">H</forename><surname>Tanahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tabira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurosci Lett</title>
		<imprint>
			<biblScope unit="volume">307</biblScope>
			<biblScope unit="page" from="9" to="12" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Raju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Gurney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Q</forename><surname>Trojanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="3155" to="3160" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis</title>
		<author>
			<persName><forename type="first">G</forename><surname>Vattemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Buxbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pastorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">358</biblScope>
			<biblScope unit="page" from="1962" to="1964" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Mosier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zaidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Gong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1219" to="1225" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Survival of cultured neurons from amyloid precursor protein knock-out mice against Alzheimer&apos;s amyloid-␤ toxicity and oxidative stress</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Galatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Maher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hesse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Multhaup</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurosci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="6207" to="6217" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Genetically engineered mouse models of neurodegenerative diseases</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Borchelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Price</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Neurosci</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="633" to="639" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Ultrastructural and histochemical study of the motor end plates of the intrinsic laryngeal muscles in amyotrophic lateral sclerosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshihara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ishii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nomoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ultrastruct Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="121" to="126" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
